JP2018536689A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536689A5 JP2018536689A5 JP2018530028A JP2018530028A JP2018536689A5 JP 2018536689 A5 JP2018536689 A5 JP 2018536689A5 JP 2018530028 A JP2018530028 A JP 2018530028A JP 2018530028 A JP2018530028 A JP 2018530028A JP 2018536689 A5 JP2018536689 A5 JP 2018536689A5
- Authority
- JP
- Japan
- Prior art keywords
- double
- nucleotides
- composition
- scap
- stranded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920002477 rna polymer Polymers 0.000 claims 14
- 239000002773 nucleotide Substances 0.000 claims 13
- 125000003729 nucleotide group Chemical group 0.000 claims 13
- 239000003795 chemical substances by application Substances 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 11
- 108091081021 Sense strand Proteins 0.000 claims 6
- 102000009822 Sterol Regulatory Element Binding Proteins Human genes 0.000 claims 6
- 108010020396 Sterol Regulatory Element Binding Proteins Proteins 0.000 claims 6
- 102100027223 Sterol regulatory element-binding protein cleavage-activating protein Human genes 0.000 claims 6
- 101710184555 Sterol regulatory element-binding protein cleavage-activating protein Proteins 0.000 claims 6
- 230000000692 anti-sense effect Effects 0.000 claims 6
- 238000012986 modification Methods 0.000 claims 6
- 230000004048 modification Effects 0.000 claims 6
- 230000014509 gene expression Effects 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- 108010006519 Molecular Chaperones Proteins 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical class CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims 1
- 101150000107 SCAP gene Proteins 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000007863 steatosis Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021203915A JP7475323B2 (ja) | 2015-12-10 | 2021-12-16 | ステロール調節エレメント結合タンパク質（ＳＲＥＢＰ）シャペロン（ＳＣＡＰ）ｉＲＮＡ組成物およびその使用方法 |
| JP2024065896A JP2024105280A (ja) | 2015-12-10 | 2024-04-16 | ステロール調節エレメント結合タンパク質（ＳＲＥＢＰ）シャペロン（ＳＣＡＰ）ｉＲＮＡ組成物およびその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562265580P | 2015-12-10 | 2015-12-10 | |
| US62/265,580 | 2015-12-10 | ||
| US201662378964P | 2016-08-24 | 2016-08-24 | |
| US62/378,964 | 2016-08-24 | ||
| PCT/US2016/065781 WO2017100542A1 (en) | 2015-12-10 | 2016-12-09 | Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021203915A Division JP7475323B2 (ja) | 2015-12-10 | 2021-12-16 | ステロール調節エレメント結合タンパク質（ＳＲＥＢＰ）シャペロン（ＳＣＡＰ）ｉＲＮＡ組成物およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018536689A JP2018536689A (ja) | 2018-12-13 |
| JP2018536689A5 true JP2018536689A5 (OSRAM) | 2020-01-30 |
Family
ID=57750612
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530028A Pending JP2018536689A (ja) | 2015-12-10 | 2016-12-09 | ステロール調節エレメント結合タンパク質（ＳＲＥＢＰ）シャペロン（ＳＣＡＰ）ｉＲＮＡ組成物およびその使用方法 |
| JP2021203915A Active JP7475323B2 (ja) | 2015-12-10 | 2021-12-16 | ステロール調節エレメント結合タンパク質（ＳＲＥＢＰ）シャペロン（ＳＣＡＰ）ｉＲＮＡ組成物およびその使用方法 |
| JP2024065896A Pending JP2024105280A (ja) | 2015-12-10 | 2024-04-16 | ステロール調節エレメント結合タンパク質（ＳＲＥＢＰ）シャペロン（ＳＣＡＰ）ｉＲＮＡ組成物およびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021203915A Active JP7475323B2 (ja) | 2015-12-10 | 2021-12-16 | ステロール調節エレメント結合タンパク質（ＳＲＥＢＰ）シャペロン（ＳＣＡＰ）ｉＲＮＡ組成物およびその使用方法 |
| JP2024065896A Pending JP2024105280A (ja) | 2015-12-10 | 2024-04-16 | ステロール調節エレメント結合タンパク質（ＳＲＥＢＰ）シャペロン（ＳＣＡＰ）ｉＲＮＡ組成物およびその使用方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (4) | US10767177B2 (OSRAM) |
| EP (1) | EP3387129A1 (OSRAM) |
| JP (3) | JP2018536689A (OSRAM) |
| WO (1) | WO2017100542A1 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3366775T4 (fi) * | 2011-11-18 | 2025-11-14 | Alnylam Pharmaceuticals Inc | Modifioituja rnai-agensseja |
| WO2017100542A1 (en) | 2015-12-10 | 2017-06-15 | Alnylam Pharmaceuticals, Inc. | Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods of use thereof |
| RU2019126483A (ru) | 2017-01-23 | 2021-02-24 | Ридженерон Фармасьютикалз, Инк. | Варианты 17-бета-гидроксистероиддегидрогеназы 13 (hsd17b13) и их применение |
| CA3059348A1 (en) | 2017-04-11 | 2018-10-18 | Regeneron Pharmaceuticals, Inc. | Assays for screening activity of modulators of members of the hydroxysteroid (17-beta) dehydrogenase (hsd17b) family |
| KR102694809B1 (ko) | 2017-10-11 | 2024-08-16 | 리제너론 파마슈티칼스 인코포레이티드 | Pnpla3 i148m 변이를 발현하는 환자의 간 질환의 치료에서의 hsd17b13의 저해 |
| JP7261494B2 (ja) | 2017-12-01 | 2023-04-20 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| EP3719128B1 (en) | 2017-12-01 | 2025-01-15 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method therefor and use thereof |
| EP3718572B1 (en) | 2017-12-01 | 2024-07-31 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method and use |
| CN118291456A (zh) | 2017-12-01 | 2024-07-05 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| JP7360716B2 (ja) | 2017-12-01 | 2023-10-13 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用 |
| JP7436030B2 (ja) | 2017-12-29 | 2024-02-21 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 複合体及びその調製方法と使用 |
| MX2020009812A (es) | 2018-03-21 | 2021-01-08 | Regeneron Pharma | COMPOSICIONES DE ARNI DE 17ß-HIDROXIESTEROIDE DESHIDROGENASA TIPO 13 (HSD17B13) Y MÉTODOS DE USO DE LAS MISMAS. |
| BR112021001613A2 (pt) | 2018-08-13 | 2021-05-04 | Alnylam Pharmaceuticals, Inc. | agentes de ácido ribonucleico de fita dupla, célula, composições farmacêuticas, métodos de inibição da expressão gênica, de inibição da replicação e de tratar um sujeito, métodos para reduzir o nível de um antígeno e para reduzir a carga viral e uso de um agente de dsrna |
| WO2020038377A1 (zh) | 2018-08-21 | 2020-02-27 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的药物组合物和缀合物及其用途 |
| US11896674B2 (en) | 2018-09-30 | 2024-02-13 | Suzhou Ribo Life Science Co., Ltd. | SiRNA conjugate, preparation method therefor and use thereof |
| HRP20231338T1 (hr) | 2018-12-20 | 2024-02-16 | Vir Biotechnology, Inc. | Kombinirana terapija hbv |
| JP7507495B2 (ja) | 2018-12-28 | 2024-06-28 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| CN113825839A (zh) * | 2019-03-20 | 2021-12-21 | 雷杰纳荣制药公司 | 用固醇调节元件结合蛋白切割激活蛋白(scap)抑制剂治疗脂质水平升高 |
| CA3133000A1 (en) | 2019-03-20 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (srebf1) inhibitors |
| CN118256498A (zh) | 2019-05-22 | 2024-06-28 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| US20220307022A1 (en) * | 2019-05-30 | 2022-09-29 | Amgen Inc. | Rnai constructs for inhibiting scap expression and methods of use thereof |
| KR20220163960A (ko) * | 2020-03-06 | 2022-12-12 | 알리고스 테라퓨틱스 인코포레이티드 | 변경된 짧은 개재성 핵산(siNA) 분자 및 이의 용도 |
| US20230323357A1 (en) * | 2020-06-09 | 2023-10-12 | Alnylam Pharmaceuticals, Inc. | TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6 (TRAF6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| IL315878A (en) * | 2022-04-15 | 2024-11-01 | Dicerna Pharmaceuticals Inc | Compounds and Methods for Modulating SCAP Activity |
| WO2024104416A1 (zh) * | 2022-11-17 | 2024-05-23 | 北京福元医药股份有限公司 | 抑制SCAP基因表达的siRNA、其缀合物和药物组合物及用途 |
| CN116059403B (zh) * | 2023-03-17 | 2024-08-16 | 常州市武进人民医院(常州市第八人民医院) | 一种胆酸修饰的红细胞囊泡及其制备方法和应用 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1861608A (en) | 1929-12-21 | 1932-06-07 | Emerson Electric Mfg Co | Fan and means for directing the air current therethrough |
| US1861108A (en) | 1930-01-24 | 1932-05-31 | Eugene O Brace | Integral clutch and transmission control |
| US3974808A (en) | 1975-07-02 | 1976-08-17 | Ford Motor Company | Air intake duct assembly |
| US4708708A (en) | 1982-12-06 | 1987-11-24 | International Paper Company | Method and apparatus for skiving and hemming |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| FR2645866B1 (fr) | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
| NL8901881A (nl) | 1989-07-20 | 1991-02-18 | Rockwool Grodan Bv | Drainagekoppelelement. |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
| WO1994000569A1 (en) | 1992-06-18 | 1994-01-06 | Genpharm International, Inc. | Methods for producing transgenic non-human animals harboring a yeast artificial chromosome |
| US5783701A (en) | 1992-09-08 | 1998-07-21 | Vertex Pharmaceuticals, Incorporated | Sulfonamide inhibitors of aspartyl protease |
| CA2156288C (en) | 1993-02-19 | 2005-10-18 | Junichi Yano | Glycerol derivative, device and pharmaceutical composition |
| US6191105B1 (en) | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
| US6054299A (en) | 1994-04-29 | 2000-04-25 | Conrad; Charles A. | Stem-loop cloning vector and method |
| US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| CA2222328C (en) | 1995-06-07 | 2012-01-10 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5858397A (en) | 1995-10-11 | 1999-01-12 | University Of British Columbia | Liposomal formulations of mitoxantrone |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
| US5994316A (en) | 1996-02-21 | 1999-11-30 | The Immune Response Corporation | Method of preparing polynucleotide-carrier complexes for delivery to cells |
| US6034135A (en) | 1997-03-06 | 2000-03-07 | Promega Biosciences, Inc. | Dimeric cationic lipids |
| AU9063398A (en) | 1997-09-12 | 1999-04-05 | Exiqon A/S | Oligonucleotide analogues |
| PL341762A1 (en) | 1997-12-24 | 2001-05-07 | Vertex Pharma | Precursors of aspartil protease inhibitors |
| US6436989B1 (en) | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
| WO2000003683A2 (en) | 1998-07-20 | 2000-01-27 | Inex Pharmaceuticals Corporation | Liposomal encapsulated nucleic acid-complexes |
| CA2345936A1 (en) | 1998-10-09 | 2000-04-20 | Ingene, Inc. | Production of ssdna in a cell |
| BR9914772A (pt) | 1998-10-09 | 2001-12-11 | Ingene Inc | Conjunto de elementos genéticos, vetor, célulahospedeira, conjunto para a produção de umasequência de ácido nucléico, método para aprodução in vivo ou in vitro de uma sequência deácido nucléico, transcrição de cdna, molécula deácido nucléico inibidor, transcrição de mrna,molécula heteroduplex e composiçãofarmacêutica |
| TNSN00027A1 (fr) | 1999-02-12 | 2005-11-10 | Vertex Pharma | Inhibiteurs de l'aspartyle protease |
| IT1318539B1 (it) | 2000-05-26 | 2003-08-27 | Italfarmaco Spa | Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente |
| US7063860B2 (en) | 2001-08-13 | 2006-06-20 | University Of Pittsburgh | Application of lipid vehicles and use for drug delivery |
| EP2213738B1 (en) * | 2002-11-14 | 2012-10-10 | Dharmacon, Inc. | siRNA molecules targeting Bcl-2 |
| US8178503B2 (en) * | 2006-03-03 | 2012-05-15 | International Business Machines Corporation | Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes |
| JP2007325525A (ja) * | 2006-06-07 | 2007-12-20 | Ikuo Wada | タンパク質分泌・輸送機構に関与する分泌・輸送機構関連タンパク質、ならびにこれらの同定・機能解析方法 |
| US7737266B2 (en) * | 2006-09-18 | 2010-06-15 | Board Of Regents, The University Of Texas System | RNAi modulation of SCAP and therapeutics uses thereof |
| KR102066189B1 (ko) | 2009-06-10 | 2020-01-14 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| WO2011005861A1 (en) | 2009-07-07 | 2011-01-13 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide end caps |
| KR102232287B1 (ko) * | 2011-06-21 | 2021-03-29 | 알닐람 파마슈티칼스 인코포레이티드 | 안지오포이에틴-유사 3(ANGPTL3) iRNA 조성물 및 그 사용 방법 |
| WO2012177639A2 (en) * | 2011-06-22 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Bioprocessing and bioproduction using avian cell lines |
| AU2012340159B2 (en) * | 2011-11-18 | 2017-09-07 | Alnylam Pharmaceuticals, Inc. | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases |
| WO2017100542A1 (en) | 2015-12-10 | 2017-06-15 | Alnylam Pharmaceuticals, Inc. | Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods of use thereof |
-
2016
- 2016-12-09 WO PCT/US2016/065781 patent/WO2017100542A1/en not_active Ceased
- 2016-12-09 EP EP16822839.3A patent/EP3387129A1/en active Pending
- 2016-12-09 JP JP2018530028A patent/JP2018536689A/ja active Pending
-
2018
- 2018-06-07 US US16/002,034 patent/US10767177B2/en active Active
-
2020
- 2020-07-27 US US16/939,119 patent/US11434487B2/en active Active
-
2021
- 2021-12-16 JP JP2021203915A patent/JP7475323B2/ja active Active
-
2022
- 2022-07-08 US US17/860,141 patent/US20230093948A1/en not_active Abandoned
-
2024
- 2024-04-16 JP JP2024065896A patent/JP2024105280A/ja active Pending
- 2024-06-10 US US18/738,165 patent/US20250034570A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018536689A5 (OSRAM) | ||
| JP6924744B2 (ja) | Ｂ型肝炎ウイルスに対する組成物および薬剤ならびにその使用 | |
| KR102623786B1 (ko) | 근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법 | |
| TWI880645B (zh) | 抑制lpa之基因表現之組合物及方法 | |
| JP2023103244A5 (OSRAM) | ||
| JP6752151B2 (ja) | 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー | |
| JP2017532038A5 (OSRAM) | ||
| JP2018529732A5 (OSRAM) | ||
| JP2014518612A5 (OSRAM) | ||
| JP2018530529A5 (OSRAM) | ||
| JP2016506240A5 (OSRAM) | ||
| JP2016520593A5 (OSRAM) | ||
| IL308752B2 (en) | RNAi factors, compositions and methods of using them for treating transthyretin-related diseases | |
| JP2017505623A5 (OSRAM) | ||
| JP2016520312A5 (OSRAM) | ||
| IL316808A (en) | Modified double-stranded RNA materials and their uses | |
| US20230056466A1 (en) | Novel precursor mirna and application thereof in tumor treatment | |
| JP2007505954A5 (OSRAM) | ||
| CN108291228A (zh) | C/EBPαSARNA组合物和使用方法 | |
| JP2019524151A5 (OSRAM) | ||
| JP2019526624A (ja) | 細胞透過性が向上したペプチド核酸複合体およびそれを含む薬学的組成物 | |
| Kanazawa et al. | Functional peptide nanocarriers for delivery of novel anti-RelA RNA interference agents as a topical treatment of atopic dermatitis | |
| JP2016531563A (ja) | 肝臓癌関連遺伝子特異的ｓｉＲＮＡ、そのようなｓｉＲＮＡを含む二重らせんオリゴＲＮＡ構造体及びこれを含む癌予防または治療用組成物 | |
| JP2016523557A (ja) | 肝臓癌関連遺伝子特異的ｓｉＲＮＡ、そのようなｓｉＲＮＡを含む二重らせんオリゴＲＮＡ構造体及びこれを含む癌予防または治療用組成物 | |
| US20240167022A1 (en) | Template directed immunomodulation for cancer therapy |